{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.14","pValueComment":"Two-sided test, significance level 0.05","statisticalMethod":"t-test, 2 sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-9.09","upperLimit":"1.82","value":"-3.64"},{"groupId":"OG001","lowerLimit":"-12.73","upperLimit":"-1.81","value":"-7.27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"description":"The UWHNSS includes ten categories-pain, disfigurement, activity, recreation/entertainment, employment, eating, saliva, taste, speech, mucus/phlegm. Patient scores on the UWHNSS range from 0 to 100 with higher scores indicating declining quality of life. Change in total score was calculated by subtracting baseline from follow-up , thus a positive change score indicates a worsening while a negative change score indicates an improvement.","dispersionType":"Inter-Quartile Range","groups":[{"description":"5mg pilocarpine by mouth 3 times a day for 12 weeks","id":"OG000","title":"Pilocarpine: Phase III"},{"description":"Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) twice weekly for 12 weeks via a Codetron unit","id":"OG001","title":"ALTENS: Phase III"}],"paramType":"MEDIAN","populationDescription":"Eligible randomized patients with both baseline and 9-month UWHNSS total scores.","reportingStatus":"POSTED","timeFrame":"Baseline and 9 months from randomization.","title":"Quality of Life (QOL) as Measured by the University of Washington Head and Neck Questionnaire (UWHNSS) Phase III","type":"SECONDARY","unitOfMeasure":"units on a scale"}